Dose response of subcutaneous GLP‐1 infusion in patients with type 2 diabetes

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2011-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1463-1326.2011.01388.xPMID 21362122
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effectiveness of progressive dose‐escalation of exenatide (exendin‐4) in reducing dose‐limiting side effects in subjects with type 2 diabetes

  2004cited by this paper
• One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

  2004cited by this paper
• Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.

  2003cited by this paper
• Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.

  2003cited by this paper
• Enhancing incretin action for the treatment of type 2 diabetes.

  2003cited by this paper
• Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.

  2003cited by this paper
• Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

  2002cited by this paper
• Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.

  2001cited by this paper
• Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

  1999cited by this paper
• Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

  1993cited by this paper

• Pharmacokinetics and safety profiles of beinaglutide injection, a recombinant human GLP-1, in adults with overweight/obesity: results from a phase I clinical trial

  2024cites this paper
• Randomised comparison of intravenous and subcutaneous routes of glucagon‐like peptide‐1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes

  2024cites this paper
• Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction

  2023cites this paper
• The correlations between steady-state concentration, duration of action and molecular weight of GLP-1RAs and their efficacy and gastrointestinal side effects in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

  2023cites this paper
• Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review

  2022cites this paper
• Pharmacotherapy for Type 2 Diabetes Mellitus: What’s Up and Coming in the Glucagon-Like Peptide-1 (GLP-1) Pipeline?

  2021cites this paper
• Who will benefit from bariatric surgery for diabetes? A protocol for an observational cohort study

  2021cites this paper
• Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

  2019cites this paper
• Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet

  2019cites this paper
• THE IMPACT OF DEGRADATION INHIBITOR OF GLUCAGON LIKE POLYPEPTIDE 1 ON BODY WEIGHT AND BETA-CELL FUNCTION IN OBESE WOMEN WITH POLYCYSTIC OVARIAN SYNDROME

  2018cites this paper
• Cooperative role of the glucagon‐like peptide‐1 receptor and β3‐adrenergic‐mediated signalling on fat mass reduction through the downregulation of PKA/AKT/AMPK signalling in the adipose tissue and muscle of rats

  2018cites this paper
• The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers

  2017cites this paper
• Weight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levels

  2016cites this paper
• Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy.

  2016cites this paper
• Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial

  2015cites this paper
• Correction to: Therapies for inter-relating diabetes and obesity – GLP-1 and obesity.

  2015cites this paper
• GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study

  2015cites this paper
• Liraglutide for Type 2 diabetes and obesity: a 2015 update

  2015cites this paper
• Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study

  2015cites this paper
• Therapies for inter-relating diabetes and obesity – GLP-1 and obesity

  2014cites this paper
• Dose response of continuous subcutaneous infusion of recombinant glucagon‐like peptide‐1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus

  2014cites this paper
• Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss

  2014cites this paper
• Combining GLP‐1 receptor agonists with insulin: therapeutic rationales and clinical findings

  2013cites this paper
• Pharmacokinetic/Pharmacodynamic Modeling of GLP-1 in Healthy Rats

  2012cites this paper